These results confirm that sCAR-T cells are a better option than classical CAR-T cells since they work as sharply as the latter against HER2+ breast cancer cells and tumors but provide an additional tool to regulate activation and side effects [310]. This evidence concerns the gene ERBB2 and breast carcinoma.